Fennec pharmaceuticals inc. (FENC)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Operating activities:
Net loss

-3,826

-3,610

-1,809

-4,730

-2,626

-2,984

-2,749

-2,587

-1,568

-2,290

-2,352

-1,598

-806

-1,143

-502

-724

-420

-540

-123

-173

177

1,388

380

-750

-3,194

1,112

-1,766

6,607

-4,108

-6,512

-764

-602

2,715

3,508

-3,144

-348

4,669

Adjustments to reconcile net loss to net cash used in operating activities:
Unrealized (gain)/loss on derivatives

-

-

0

0

-

0

0

0

167

206

-183

-120

-37

3

19

-17

43

11

216

385

625

-

619

181

-

1,523

-1,708

7,535

-3,573

-

-139

645

-

-

-2,221

225

-

Amortization of deferred issuance cost

17

18

17

17

12

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on derivative settlement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

379

-

-2,655

-

-

-

-

-

-

-

3,327

-

-

-

5,680

Unrealized gain on derivative settlement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

Non-cash settlement of Cadherin litigation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

Unrealized foreign exchange loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

6

0

13

-10

Loss on impairment of capital assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

Amortization of deferred lease inducements

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

Non-cash severance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

-

-

-

-

-

Non-cash severance expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Stock-based compensation - contractors

21

22

21

331

43

29

46

83

114

189

210

286

56

30

28

17

13

0

0

0

0

183

122

0

129

-2

27

0

0

114

3

35

0

43

29

49

0

Stock-based compensation - employees

391

461

314

1,669

221

222

222

1,207

174

108

907

461

41

463

41

111

0

69

9

10

9

88

67

339

133

-8

41

29

0

157

0

17

0

0

129

0

0

Changes in operating assets and liabilities:
Prepaid assets

-6

-161

331

-52

-60

-243

351

-47

-21

-70

177

-11

-11

2

23

-22

-36

-7

69

-17

-17

-19

42

-29

-27

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

2

-

-

-

-15

4

4

6

-5

-

-

-

-

-

-

-

-

-

-

-

-

Other current assets

-6

-

-1

-3

3

-

-4

-6

-3

-

-4

1

2

-

-3

-

-

-

-2

1

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

63

824

-440

-70

266

-834

1,157

-324

178

363

196

71

-19

8

-110

120

-72

45

-149

17

76

-56

30

180

-58

-

-

-

-

-

-

-

-

-

-

-

-

Accrued liabilities

-427

542

-8

-28

-452

395

72

-2

-482

457

71

-38

7

37

38

-31

-11

6

37

4

-87

94

2

-21

-75

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-470

-499

-424

-509

-511

-418

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acquired in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

Changes in operating assets and liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

24

479

-10

-128

-288

104

-62

-34

2,472

-129

-2,309

47

Net cash used in operating activities

-3,749

-1,590

-2,235

-2,756

-2,479

-2,930

-1,599

-1,570

-1,727

-1,320

-958

-688

-675

-

-544

-

-

-

-

-

-

-

-443

-410

-378

-445

-469

-889

-407

-557

-726

-1,133

-578

-3,314

-636

1,772

-1,048

Purchase of capital assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

Disposal of capital assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

Proceeds from sale of assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

Release of restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

Release of restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

Purchase of short-term investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

Redemption of short-term investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

Investment in Cadherin Biomedical Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

Acquired intellectual property rights

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

Net cash used in investing activity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Financing activities:
Capitalized deferred issuance cost

0

-

0

0

71

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Options and warrants exercised

-

-

0

0

-

-

483

473

186

-

383

98

0

-

0

6

102

-

21

449

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of units, net of issue costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

-

-

0

0

-

Issuance of units, net of issue costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

Cash paid for issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

Conversion of long-term debt to equity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

Long-term debt repayment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

Capital lease repayments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

Issuance of shares, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

27

-

-

-

-

-

0

0

-

-

-

-

0

-

-

-

0

Short swing profit judgment offset with settlement expense

-

-

0

0

-

-

0

18

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Financing expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

Proceeds from convertible note

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

Other liability repayments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

Security deposits received

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

Issuance of shares, options exercise

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-21

21

87

53

0

0

0

0

0

0

0

0

0

0

0

0

Private placement

-

-

-

-

-

-

-

-

-

-

31

7,571

-

-

0

5,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Rights offering

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,006

102

0

21

449

27

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in financing activities

0

0

0

0

-71

1,187

483

491

186

19,892

414

7,669

0

-

0

-

-

-

-

-

-

-

21

87

53

1,570

0

0

0

0

0

0

0

2,566

0

0

0

Decrease in cash and cash equivalents

-3,749

-1,590

-2,235

-2,756

-2,550

-

-1,116

-1,079

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Effect of exchange rate on cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

0

-

0

-

0

-110

-19

15

124

Decrease in cash and cash equivalents

-

-

-

-

-

-

-

-

-1,541

18,572

-544

6,981

-675

-611

-544

4,536

-397

-424

-488

-62

-391

1,714

-422

-323

-325

1,125

-469

-889

-407

-557

-726

-1,133

-578

-877

-636

1,787

-924

Supplemental non-cash disclosure:
Non-cash deferred issuance cost (warrant value)

0

0

0

0

255

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-